We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Full Fed. Circ. Urged To Review 'Unclear' Double-Patent Rules

Law360 (January 8, 2019, 7:31 PM EST) -- Generics maker Hikma asked the full Federal Circuit Monday to rehear a decision that a Novartis cancer drug patent is not invalid for double-patenting, saying the ruling conflicts with precedent and...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.